Department of Pathology Microbiology and Immunology

December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

October 28, 2021

VUMC researchers a step closer to broad ebolavirus protection

October 13, 2021

Diagnostic Laboratory Services set for relocation, expansion

Vanderbilt’s Diagnostic Laboratory Services are undergoing a major relocation and expansion project.

October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.